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1. Introduction 
Ornithine decarboxylase (ODC, EC 4.1.1.17, the 
first enzyme in the pathway of polyamine biosynthesis), 
has one of the shortest in vivo half lives yet reported 
[ I] , making it an ideal enzyme for studying enzyme 
inactivation. Much effort has been applied to the 
problem of the hormoral stimulation of ornithine 
decarboxylase activity (see reviews, [2-41) but the 
equally important phase of ODC inactivation [5-81 
has not been as extensively studied. 
The highest specific activity of ODC in mammalian 
organs [9,10] has been found in gonadotrophin- 
treated immature rat ovaries 4 h after injection of 
luteinizing hormone (LH). We also found that the 
follicular tissue is the ovarian compartment most 
response to this action of LH [ 111. In the present 
study, we report that the ODC activity in extracts of 
follicle-rich ovaries is stable in vitro in the absence of 
pyridoxal phosphate (P<P), in contrast to enzyme 
preparations from other sources. This provided us 
with a test system in which we could demonstrate 
the presence of an ornithine decarboxylase inactivating 
factor (ODIF) in extracts of young adult prostate 
glands that can be separated from ODC activity. 
2. Materials and methods 
2.1. Hormones and other biochemicals 
Pregnant mare serum gonadotrophin (PMSG, 
*In partial fulfilment of the requirements for a Ph D. 
degree of the Feinberg Graduate School of the Wcizmann 
Institute of Science. 
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Gestyl) was a product of Organon, Oss, The Netherlands. 
Ovine luteinizing hormone (NIH-LH-18) was kindly 
supplied by the National Institute of Arthritis and 
Metabolic Disease, Bethesda Md. USA [ l-14C]DL 
Ornithine (3.0 mCi/mmol) and [ 1 -r4C] S-adenosyl-l- 
methionine (2.43 mCi/mmol) were purchased from 
New England Nuclear Corp. Boston Mass. USA. 
Protamine phosphate was prepared enzymatically 
[ 121 from protamine sulfate (Fluka A.G. Buchs, 
Switzerland). 
2.2. Animals and enzyme extracts 
Female Wistar rats were injected subcutaneously 
with 10 i.u. PMSG and 52 h later intraperitoneally 
with 30 pg LH and killed 4 h after the LH injection. The 
ovaries were dissected free of fat, homogenized in an 
all-glass Potter-Elvehjem homogenizer (0.005-0.007 
in clearance) in 0.25 M sucrose containing 10 mM 
Tris-HCl, pH 7.5, 5 mM dithiothreitol and 0.1 mM 
disodium ethylenediaminetetraacetate and centrifuged 
at 150 000 g,, for 30 min. Ventral prostate glands 
were dissected from 3-4 month old rats, homogenized 
and centrifuged as described above. The supernatant 
solutions were subjected to gel filtration on a column 
(0.7 X 13 cm) of Sephadex G-25 equilibrated with a 
medium of similar compositions but lacking sucrose 
(TDE buffer). 
Assays for ODC activity were performed at 2 con- 
centrations of enzyme (one double the other) as 
described previously [IO] . 
3. Results 
Ornithine decarboxylase (ODC) activity extracted 
from the ovaries of rats treated with PMSG and LH 
North-Holland Publishing Company - Amsterdam 
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Fig.1. Stability of ODC in extracts from different organs to 
inactivation at 37°C. High speed supernatant solutions 
(150 OOOg) were prepared [IO] from either prostate glands 
of 4 month old rats (a- 0) or from ovaries (0 -0) of 
26 day old gonadotrophin treated rats (v. section 2.2). The 
supernatant solutions were subjected to gel filtration through 
a Sephadex G25 column and preincubated for the indicated 
periods of time at 37°C before assay of ODC activity as 
described previously [lo]. Mixtures of the two extracts were 
made at 4:l (a -A)or8:1(0 ---0) ratio of prostatic to 
ovarian protein. Initial (100%) activity values were 1.79‘nmol 
14C0, liberated/h/mg protein and 32.3 nmoles 14C0,/h/mg 
protein for prostatic and ovarian extracts respectively. 
has a half life of more than one hour when incubated 
at 37’C in the absence of its coenzyme pyridoxal 
phosphate (PLP); an enzyme preparation from ventral 
prostate gland had a half life of only 8 min (fig. 1). The 
activity of mixtures of the two enzyme preparations 
(fig.1) showed a half-life of 13 min (4: 1 ratio of 
prostatic to ovarian protein) and 10 min (8: 1 ratio) 
respectively. Inactivation of ovarian ODC by addition 
of a prostatic extract was not observed (after 30 min) 
at 0°C or when the prostate extract was boiled before 
incubation at 37”. 
The inactivation of ovarian ODC by a prostatic 
extract was not inhibited by anti-proteolytic agents 
such as the Kallikrein inhibitors Trasylol SK/TK/l 
(1000 &ml, 500 KIU/mg) or Trasylol GOS 746/3 1 
(1000 pg/ml, 5700 KIU/mg) from Bayer A.G. 
Elberfeld, Germany, benzamidine (8 mg/ml) from 
Eastman Kodak Co., Rochester, N.Y., USA., tosyl- 
lysyl-chloromethyl ketone (2 pg/ml) from Sigma 
Chemical Co., St. Louis, MO., USA, or phenyl-methyl- 
sulfonyl chloride (1 0e3 M) and diisopropyl fluoro- 
phosphate (10-j M) from Calbiochem, A.G., Lucerne, 
Switzerland. 
The specificity of the inactivating factor present 
in a prostatic extract for ODC compared to other 
enzymes is shown in table 1. Only ODC showed a 
loss of activity upon incubation of the prostate 
extract for 15 min at 37°C whereas the PLP dependent 
enzyme [ 131 S-adenosyl-methionine decarboxylase 
(EC. 4.1.1.50, the next enzyme in the pathway of 
polyamine biosynthesis) showed some increase in 
activity. Three metabolically unrelated enzymes, 
phosphoprotein phosphohydrolase (EC 3.1.3.16), 
glucose 6-phosphate dehydrogenase (EC 1.1 .1.49) and 
6 phospho-gluconate dehydrogenase (EC 1.1.1.47) 
maintained their activities. ODC was protected against 
inactivation by 1 OW4 M PLP, and some increase of 
activity was observed; the other enzymes studied 
showed no change upon incubation with PLP. 
In order to assess quantitatively the ability of a 
prostatic extract to inactivate ODC, we considered a 
unit of ODC activity as that activity which catalyzes 
the release of 1 nmol “C02/h [IO] ; we defined a 
unit of ornithine decarboxylase inactivating factor as 
that activity which results in a decrease of 1 unit of 
ODC activity in 1 h preincubation at 37°C. Measure- 
ments of ODIF were made using 180 units per ml of 
ODC as substrate and a 15 min preincubation period. 
ODIF activity was proportional to protein concentra- 
tion in the range tested. 
When a prostatic extract was subjected to precipita- 
tion at pH 4.6 by the method of Ono et al. [14], the 
precipitate showed a 3-fold increase in the specific 
activity of ODC accompanied by a halving of the 
specific activity of ODC inactivating factor (table 2). 
The supernatant solution showed negligible ODC 
activity and nearly a doubling in its ODIF specific 
activity. The ODIF activity in the supernatant solution 
represented 86% of the initial ODIF activity. An 
independent fractionation of a second pool of prostate 
glands resulted in a similar separation of ODC and 
ODIF activity with an increase of the specific activity 
of ODC in the pH 4.6 precipitate of 2.4-fold and an 
increase in the specific activity of ODIF in the super- 
natant of 2.2-fold. 
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Table 1 
Stability of different prostatic enzyme activities at 37°C in 
the presence and absence of PLP 
% Activity remaining after 
incubation at 37°C for 15 mm 
Enzyme Without 
pyridoxal 
phosphate 
With 
pyridoxal 
phosphate 
Ornithine decarboxylase 62 129 
S-adenosyl-1-methionine decarboxylase 125 109 
Phosphoprotein phosphohydrolase 102 102 
Glucose 6-phosphate dehydrogenase 96 88 
6-Phosphogluconate dehydrogenase 98 99 
A high speed supernatant solution (150 OOOg) was prepared [lo] from the 
prostate glands of 3 month old rats and subjected to gel filtration as described in 
section 2.2. Analysis of enzymic activities was made before and after incubation 
for 15 min at 37°C in the presence and in the absence of 10e4 M pyridoxal 
phosphate. Assays for ODC activity [lo] and Sadenosyl-1-methionine decarboxy- 
lase activity [20] were carried out in the presence of pyridoxa] phosphate and 
based on the release of “CO, from [l-Y] DL ornithine and [ l-‘4C]S-adenosyl-l- 
methionine. Phosphoprotein phosphohydrolase was assayed [ 121 by the release 
of ‘*P from protamine phosphate (179 counts/pmole phosphate). Glucose 6- 
phosphate dehydrogenase [ 211 and 6-phosphogluconate dehydrogenase [21] 
were assayed spectrophotometrically. The 14C0, radioactivity was detected by 
liquid scintillation counting [ZO] and ‘*P by Cerenkov radiation [22]. The initial 
(100%) values were: ODC, 2.08 nmol “CO, liberated/h/mg protein; S-adenosyl-l- 
methionine decarboxylase, 3.24 nmol YO, liberated/h/mg protein; phospho- 
protein phosphatase, 1.58 nmol 32P released/mg protein/l0 min; glucose 6-phos- 
phate dehydrogenase O.O20/units/mg protein (211; and 6-phosphogluconate 
dehydrogenase 0.0158 units/mg protein [21]. 
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4. Discussion 
The half life of ODC activity of 8 min in vitro for 
a prostatic enzyme in the absence of PLP (which is 
close to that of 12-20 min found for liver ODC in vivo 
[l] could be due to: 
1. Inherent instability of the enzyme. 
2. Enzyme modification, or 
3. Proteolytic degradation of ODC. 
We have shown that a high speed prostatic super- 
natant which has been freed from low molecular 
weight constituents by gel filtration through Sephadex 
G-25 is able to produce a decrease in the activity of an 
ovarian ODC preparation. 
The possibility of inherent instability of prostate 
ODC is unlikely since a form of ODC which is stable 
in the absence of PLP is found in gonadotrophin 
treated ovaries. This enzyme has a K, for PLP of 
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0.73 PM cf. [lo] while the prostatic ODC (unstable) 
has a KM of 2.15 ,uM, similar enough to suggest, in 
the absence of any evidence to the contrary, that 
ODC structure in these two organs is closely related. 
ODC activity could be modified by the addition 
or the removal of certain residues. The possibility 
that the inactivation of ODC is brought about by 
addition of low molecular weight groups is rendered 
unlikely by the fact that the extracts have been sub- 
jected to gel filtration for removal of such low mole- 
cular weight components. The effectiveness of this 
procedure is shown by the fact that both ovarian and 
prostatic extracts show complete dependence on added 
PLP for activity. The possibility that ODC may be 
modified and thus inactivated by removal of one or 
more groups, requires further study. 
The third possibility of a proteolytic cleavage of 
ODC being involved in its inactivation [ 151 although 
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Table 2 
Separation of the ODC inactivating factor of rat prostate from ODC 
Fraction Total Protein ODC Activity ODIF Activity 
(mg) (units) (units) 
Sephadex G25 filtrate 71.8 333 3487 
pH 4.6 pellet 20.5 261 508 
pH 4.6 supernatant 37.9 4 3016 
A high speed supernatant solution (150 000 g) was prepared from the prostate 
glands of four month old rats as described in section 2.2. The Sephadex (G25) 
filtrate was brought to pH 4.6 by gradual addition of 0.5 M acetic acid with con- 
stant stirring at 0-4°C. The suspension was centrifuged at 38 000 g,,, for 5 min 
at O”C, and the resulting precipitate was resuspended in 1.5 ml of TDE buffer. The 
supernatant solution was subjected to gel filtration through a 0.7 X 13 cm column 
of Sephadex G25 equilibrated with TDE buffer. ODC inactivating factor activity 
(ODIF) was determined by incubation, for 15 min at 37”C, of 79-155 pg of 
protein from a prostatic extract (containing O.Ol- 1.7 units of ODC activity) in 
the presence of 290 pg of protein from an extract of ovaries (see 2.2) obtained 
from gonadotrophin treated rats (containing 9 units of ODC activity) in a total 
volume of 50 ~1. Incubations were terminated by addition of cold buffer con- 
taining pyridoxal phosphate, ornithine and DTT, allowing direct determination of 
the remaining ODC activity as described [lo]. Assays for both activities were 
performed in duplicate. Activity units are defined in section 3. 
attractive, has not been proven. However, the recent 
report of HGltt% [ 161 that the activity of rat liver 
ODC after treatment which cycloheximide decreases 
in parallel with the decrease in immunoreactive enzyme 
protein suggests a degradation process is involved. 
We have not yet found an antiproteolytic agent 
that’prevents the inactivation of ODC, although a 
variety of agents were tested at or near the maximal 
concentration which does not interfere with the 
ODC assay. If, indeed, a proteolytic enzyme is involved 
in the inactivation of ODC, it is probably not one of 
the ‘group specific proteases’ described by Katunuma 
[ 151. The evidence for this is: (a) we do not find a 
detectable in vitro inactivation of S-adenosyl-l- 
methionine decarboxylase, another PLP dependent 
enzyme [ 131, which has a half life in vivo of approx- 
imately 60 min [ 171 and (b) we were unable to sup- 
press the inactivation of ODC by addition of diiso- 
propyl fluorophosphate which is effective against the 
proteases described by Katunuma as acting specifically 
against PLP apoenzymes [IS]. 
Pegg and Williams-Ashman [ 181 and Jgnne and 
Williams-Ashman [9] have reported a protecting effect 
of PLP on preparatiqns of rat ventral prostate ODC 
at low temperatures. In a study of the stability 
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of another PLP dependent enzyme, glutamic decar- 
boxylase from E. coli, Shukuya and Schwert [ 191 
showed that PLP has a stabilizing effect at 25°C similar 
to the effect shown on ODC in table 1. Whether the 
PLP protection of rat prostatic ODC shown here is 
mediated by a direct effect of the cofactor on the 
enzyme or by PLP binding to ODIF remains an open 
question. 
The possibility that the ODC inactivating factor 
reported here is itself under hormonal regulation (which 
may also be a factor in the variation in the rate of 
inactivation of ODC in crude prostatic extracts, cf. 
table 1 and fig. 1) is presently being investigated. 
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